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The aim of the study was to determine drug concentration ratios
between oral fluid collected with the Intercept device and whole
blood. Samples of blood and oral fluid were obtained from patients
admitted to acute psychiatric treatment and drivers suspected of
drugged driving. Samples were analyzed for illegal drugs,
benzodiazepines, opioids, carisoprodol, and meprobamate. Drugs
were detected in samples of both blood and oral fluid from 59
subjects; altogether, 17 different drugs were found. Concentration
ratios between oral fluid and blood were determined for all cases.
The distributions of drug concentration ratios were wide for most
drugs and do not allow reliable estimations of drug concentrations
in blood using concentrations in oral fluid. The median oral
fluid/blood drug concentration ratios for the most prevalent drugs
were 0.036 diazepam, 0.027 nordiazepam, 7.1 amphetamine,
2.9 methamphetamine, 5.4 codeine, 1.9 morphine, and 4.7
tetrahydrocannabinol. The correlation coefficients between drug
concentrations in oral fluid and blood ranged from 0.15 to 0.96 for
the six most prevalent drugs.
Introduction
Samples of oral fluid (mixed saliva) may be used to detect the
use of alcohol, medicinal drugs, and illegal drugs (1–4). Al-
though drugs may be detected in urine for several days after
use and even weeks for cannabis, most drugs may be detected
in oral fluid for approximately the same length of time as in
blood (5). Many kits for sampling oral fluid are available. The
collection may be performed by placing a collection pad be-
tween cheek and gums or under the tongue for 2–5 min, fol-
lowed by transfer of the pad to a vial containing a conservation
buffer. The collection pads of some brands may contain saliva-
stimulating agents (6,7).
The transfer of a drug from blood to oral fluid, and hence the
concentration ratio between fluid and blood (OF/B ratio), de-
pends on the compound’s physicochemical properties, namely
pKa, protein binding, lipophilicity, molecular weight, and spa-
tial configuration (5). For drugs with pKa close to the pH of
oral fluid, which normally is between pH 6.0 and 7.0 (8) (e.g.,
amphetamines and opioids), the pH of the individual’s oral
fluid may greatly affect the OF/B ratio. The route of drug ad-
ministration may also affect the drug concentration in oral
fluid, and in addition, the sampling procedure and the prop-
erties of the sampling device may also affect the determined
drug concentration (5–7,9–11).
The Intercept collection device is often used for the collec-
tion of oral fluid. The collection pad is treated with a solution
containing citric acid and sodium chloride to stimulate the
production of oral fluid, which may affect the drug concentra-
tion in the sampled oral fluid. The recovery for tetrahydro-
cannabinol (THC) from this sampling device is low, but the re-
coveries for many other drugs are fairly good (6).
Data on OF/B ratios for this collection device are needed in
order to better assess analytical results from single patients
and large populations. However, few studies on OF/B ratios for
the Intercept collection device have so far been published
(12–14).
OF/B ratios for different drugs are often determined in phar-
macokinetic studies. We believe that the interindividual vari-
ation between random drug users may be greater than the
variation observed in well-controlled pharmacokinetic studies.
The aim of this study is to investigate the variation in indi-
vidual OF/B drug concentration ratios in samples from pa-
tients and suspected drugged drivers when using the Intercept
collection device and to determine the average and median
OF/B ratios for several drugs.
Materials and Methods
Samples of oral fluid and blood were collected from patients
admitted to acute psychiatric treatment at Lovisenberg Dea-
conal Hospital (Oslo, Norway) or Sørlandet Hospital (Arendal,
Norway) from September 2006 to May 2007 and from motor
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vehicle drivers suspected of driving under the influence of
drugs apprehended by the police from August 2004 to
November 2005 (15). The hospital patients volunteered in a
study of drug use among acute psychiatric patients (Mordal et
al., manuscript in preparation). Samples of blood and oral fluid
were taken by hospital staff shortly after admission, and results
were used for research purposes only. The study of motor ve-
hicle drivers was a part of the Roadside Testing Assessment pro-
ject Rosita-2 (16). Samples of whole blood were taken by police
physicians for forensic purposes, while samples of oral fluid
were given voluntarily for research purposes.
Oral fluid was sampled using the Intercept oral fluid sam-
pling kit from Orasure Technologies (Bethlehem, PA). Samples
of whole blood were collected using 5-mL Vacutainer® tubes
containing fluoride and heparin (BD Diagnostics, Franklin
Lakes, NJ). Samples of oral fluid and blood were frozen within
a few days after arrival at the laboratory and analyzed for drugs
within a few weeks after sampling.
Samples were excluded from the study if the time lapse be-
tween sampling of blood and oral fluid exceeded 10% of one
half-life in blood (17) or if the volume of collected oral fluid was
less than 0.2 mL, an amount that is regarded to be too small for
accurate determination of the oral fluid dilution factor.
The Intercept oral fluid sampling kit contained 0.8 mL buffer
with Flag Blue dye. The dilution of oral fluid with buffer was de-
termined by analyzing the concentration of Flag Blue dye in the
oral fluid/buffer mixture by using high-performance liquid chro-
matography (HPLC) with UV detection using a modification of
a previously published method (18). The following modifica-
tions were implemented: the HPLC system consisted of a Waters
Alliance 2695 system with a diode-array detector (Milford, MA).
A Waters XTerra Phenyl HPLC column was used (150 × 2.1-
mm i.d.). Themobile phase was composed of 10mM ammonium
formate pH 4 with an acetonitrile gradient.
Each sample was diluted 1:4 (v/v), and 10
µL was injected. The column effluent was
monitored at 629 nm. Samples were stored
at about –20°C until the analysis of Flag
Blue dye was performed.
All drug concentrations presented in
this study are concentrations in undiluted
oral fluid calculated by dividing the drug
concentration found in the oral fluid/
buffer mixture with the determined dilu-
tion factor.
Drug concentrations in samples of oral
fluid were determined using HPLC with
tandem mass spectroscopic detection
(MS–MS) (19). Samples of blood were
screened for amphetamines, cannabi-
noids, cocaine metabolites, and opiates
using Enzyme Multiplied Immunoassay
Technique (EMIT) (20). Screening for
other drugs was performed using HPLC–
MS (21). Drug findings were confirmed
and quantified using gas chromatog-
raphy–MS or LC–MS (21–24). The labo-
ratory was accreditated according to ISO
17025 for performing these confirmation and quantification
methods for forensic toxicology purposes by the Norwegian
body for accreditation of laboratories (Norsk Akkreditering,
Kjeller, Norway). Cutoff thresholds are presented in Table I. The
cutoff thresholds were more than than the limit of quantitation
(LOQ) of the analytical methods and were also set to exclude
low drug concentrations without pharmacological or toxico-
logical importance.
Correlations between drug concentrations in blood and oral
fluid were determined by linear regression. Pearson’s product-
moment correlation coefficients (r) were calculated. Pearson’s
second coefficient of skewness was used to determine the skew-
ness of the OF/B ratios.
Results
Altogether, 90 pairs of blood and oral fluid from patients
and 22 pairs of blood and oral fluid from suspected drugged
drivers were available for comparison of drug concentrations.
The volume of oral fluid collected ranged from 0.2 to 1.8 mL
with a median of 0.6 mL.
Drugs were found in oral fluid and/or blood from 37 of the
patients and all of the suspected drugged drivers. Two obvious
outliers were excluded for flunitrazepam and clonazepam; in
those cases, the OF/B ratios were 35 or 137 times larger than
the median OF/B ratio and might have been caused by residual
tablet ingredients in the mouth due to recent tablet intake.
The most frequently detected drugs were diazepam, nor-
diazepam, amphetamine, methamphetamine, THC, and mor-
phine. Drug concentrations in oral fluid and blood for am-
phetamine, methamphetamine, diazepam, and nordiazepam are
Table I. Analytical Cutoff Concentrations for Drugs in Blood and Oral Fluid as
Analyzed by GC–MS or LC–MS
Cutoff Concentrations (µg/L)
Oral fluid/
Drug Blood buffer mixture
Tetrahydrocannabinol 1 1
Flunitrazepam 0.8 0.3
Clonazepam 10 0.5
Nitrazepam 10 0.5
Alprazolam 10 1
Zopiclone 10 1
Diazepam 30 1
Nordiazepam 30 1
Oxazepam 150 5
Amphetamine 40 5
Methamphetamine 40 5
3,4-Methylenedioxy-N-methylamphetamine (MDMA) 40 5
Codeine 5 2.5
Morphine 10 5
Methadone 30 5
Carisoprodol 500 10
Meprobamate 1000 20
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presented in Figure 1. Only cases in which drugs were more than
the cutoff thresholds in both oral fluid and blood are presented.
The correlation coefficients (r) were 0.95 for amphetamine,
0.96 for methamphetamine, 0.61 for diazepam, 0.95 for nor-
diazepam, 0.15 for THC, and 0.85 for morphine.
Individual drug concentration ratios between oral fluid and
blood are listed in Table II. The median OF/B ratios were less
than 0.2 for carisoprodol and all benzodiazepines except al-
prazolam, in the intermediate range of 0.2–2 for meproba-
mate, alprazolam, methadone, and morphine, and more than
2 for amphetamines, zopiclone, THC, and codeine.
The distribution of OF/B ratios was wide for most com-
pounds. Pearson’s coefficient of skewness was larger than 0.5
for nine of the drugs detected. The distributions of OF/B ratios
for codeine, methadone, and morphine were much skewed
with coefficients of skewness larger than 1.3.
Discussion
The results of our study show large interindividual variations
in drug concentration ratios between oral fluid and blood.
This wide range of OF/B ratios does not allow reliable estima-
tions of drug concentrations in blood based on drug concen-
trations in oral fluid. Similar variations have also been found
in the Rosita-2 study (12); however, in that study the actual oral
fluid dilution was determined only by a few of the participating
laboratories. In most cases, the average dilution factor was
used. The observed distribution of OF/B ratios for some drugs
were skewed, particularly for opiates. The wide variation of
OF/B ratios caused a number of samples to be positive for a
drug in either blood or oral fluid and negative in the other type
of specimen (results not shown).
The OF/B ratio for zopiclone was fairly high with a median
of 3.8. An oral fluid/plasma (OF/P) ratio of 2.2 has previously
been reported (25). As the reported blood/plasma ratio for
zopiclone is 1.0 (26), the OF/B ratio would also be 2.2, which
is within the range observed in our study. However, a different
sampling procedure for collecting oral fluid was used in our
study; this may have affected the OF/B ratio.
A high OF/B ratio was observed for amphetamine with a
median ratio of 7.1. This is significantly higher than the theo-
retical ratio of 3.33 (5) but lower than the median ratio of
13.4 found in the Rosita-2 study (11). A low drug concentration
ratio between oral fluid and plasma of 2.76 has also been re-
ported (27). These large differences may reflect differences in
drug administration and sampling of oral fluid in those studies
in addition to variations between individuals.
The median OF/B ratio for THC of 4.7 was fairly low com-
pared to the overall result for the Rosita-2 study in which a me-
dian OF/B ratio of 15 was found (12). However, OF/P ratios for
THC as low as 0.5–2.2 have also been reported in a pharma-
cokinetic study (28).
It has been claimed that the concentration of THC in oral
fluid is primarily a result of contamination of the oral cavity
by THC when smoking cannabis (5,29). The decline in THC
concentration may therefore be primarily due to removal of
THC from the oral cavity (e.g., by eating, drinking, or swal-
lowing oral fluid) and, to a lesser extent, absorption. The THC
concentration in oral fluid therefore does not depend on the
THC concentration in blood or serum. The observation of
similar elimination rates for THC in oral fluid and serum is
Figure 1. Concentrations of amphetamine, methamphetamine, diazepam,
and nordiazepam in blood and oral fluid from suspected drugged drivers
() and from patients (∆).
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probably accidental (30). Large interindividual variations in
OF/B ratio have been also been reported previously (12,30),
and a poor correlation between the magnitude of performance
impairment and THC concentration in oral fluid has been
found (31).
The THC concentrations observed in blood and oral fluid in
our study were in most cases fairly low, indicating that
cannabis was smoked a number of hours ago. This may be one
reason for the low ratios observed in our study. In addition, the
recovery for THC from the Intercept collection kit is low (6);
however, the same type of oral fluid sampling device was used
in the Rosita-2 project, so the type of sampling kit does not ex-
plain the difference between our result and the overall results
for Rosita-2.
Other drugs with high OF/B ratios were MDMA (4.6),
codeine (5.4), and methamphetamine (2.9). Previously pub-
lished OF/B and OF/P ratios for these drugs also vary signifi-
cantly (10–12,32–35).
Benzodiazepines had low OF/B ratios, the median ratios
were 0.036 for diazepam, 0.027 for nordiazepam, 0.056 for ox-
azepam, 0.090 for nitrazepam, 0.16 for flunitrazepam, and
0.17 for clonazepam; some median ratios are based on few in-
dividual determinations and therefore may not be representa-
tive for larger populations. For alprazolam, a single ratio of
0.36 was observed.
Our result for diazepam is similar to findings in several
other studies. A previously reported median OF/B ratio was
0.02 (12), and previously reported average OF/P ratios for di-
azepam were 0.016–0.029 (36–39). With a blood/plasma ratio
of 0.6 (17), the average OF/B ratio for these four studies is
0.035. Oral fluid was in these latter studies collected by spitting
with or without stimulation by chewing Parafilm® or Teflon®.
In another study, a lower OF/B ratio of 0.016 ± 0.002 was re-
ported using free-flowing oral fluid (40).
In a previous study of nitrazepam, OF/serum ratios of 0.04–
0.08 were observed (41); data on the serum/blood ratio or OF/B
ratio have not been published. In a study of oxazepam, an av-
erage OF/B ratio of 0.05 was observed when oral fluid was col-
lected by spitting (42), which is lower than the average ob-
served in our study but similar to the median.
The low OF/B ratios for benzodiazepines is primarily due to
the fact that these drugs have high protein binding, and the
Table II. Drug Concentration Ratios Between Oral Fluid and Blood
Individual 1.8 0.6 2.7 0.36 0.15 0.010 0.009 0.027 0.01 0.10 1.7 0.3 1.9 0.4 0.07 0.2 0.4
ratios
2.2 2.0 4.2 0.16 0.019 0.012 0.043 0.05 0.10 2.7 1.4 2.4 0.5 0.6
2.2 2.1 5.1 0.17 0.020 0.014 0.053 0.07 0.15 5.0 1.6 4.4 0.6 1.4
3.7 2.1 8.3 0.18 0.021 0.022 0.056 0.09 0.16 5.2 1.6 5.4 0.7 1.8
3.9 2.6 0.27 0.021 0.023 0.058 0.13 0.17 1.7 7.8 3.6 3.0
4.6 2.9 0.022 0.024 0.065 0.13 0.73 2.0 22.4 7.2 4.7
4.7 4.4 0.022 0.025 0.254 0.13 7.0 35.7 5.2
7.1 5.0 0.023 0.025 14.8 6.1
7.6 5.5 0.025 0.026 17.0 6.9
8.7 9.1 0.032 0.026 20.2 18.3
8.9 13.6 0.035 0.027 41.5
9.5 0.037 0.027
12.2 0.038 0.028
14.2 0.039 0.030
17.5 0.043 0.034
0.045 0.036
0.046 0.041
0.049 0.048
0.049 0.049
0.054 0.078
0.093
0.119
Mean 7.2 4.5 5.1 0.36 0.19 0.039 0.030 0.080 0.087 0.23 3.7 6.8 11.4 2.2 0.1 0.2 8.2
RSD (%) 65 84 47 26 64 51 98 52 105 46 113 112 127 148
Median 7.1 2.9 4.6 0.17 0.036 0.027 0.056 0.090 0.16 3.8 1.9 5.4 0.7 4.7
Skewness 0.1 1.3 0.5 1.2 0.4 0.7 0.9 -0.2 1.0 -0.3 1.9 1.4 1.6 0.9
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free fractions in blood therefore are low. Differences in OF/B ra-
tios for different benzodiazepines may be related to differences
in protein binding (43).
Almost all individual OF/B ratios observed in this study fall
within the ranges observed in the Rosita-2 study (12). For
that report, the actual oral fluid volume was used to calculate
drug concentrations in undiluted oral fluid only by a few lab-
oratories not including the Norwegian data. In our study, we
have determined the dilution of oral fluid by analyzing the
concentration of the blue coloring agent in the oral fluid-
buffer mixture, and the Rosita-2 results presented here there-
fore are better reflecting the actual concentrations in undi-
luted oral fluid.
Some drugs may lower the secretion of oral fluid (e.g.,
cannabis, stimulants, and some medicinal drugs). In cases of
dry mouth, the sample volume of oral fluid may be significantly
lower than average sampling volumes, even if a volume indi-
cator suggests that sufficient volume has been collected. The
collected volume of oral fluid therefore should be determined
if the aim is to estimate the drug concentration in undiluted
oral fluid. The easiest way would be to weigh the samples be-
fore analytical testing; the drug concentrations in undiluted
oral fluid may then easily be calculated. This was not done in
our study. Instead, we determined the dilution by determining
the concentration of the blue coloring agent, which is pre-
sent in the buffer mixture of the Intercept collection kit. The
primary advantage with our procedure is that variations in
the buffer content in the oral fluid sampling kit do not affect
the calculation of the dilution factor for oral fluid.
Conclusions
We observed large variations in drug concentration ratios be-
tween oral fluid and blood for a number of drugs. These results
may better reflect the real-life variation in drug concentra-
tion ratios than those observed in some well-controlled phar-
macokinetic studies. Our findings indicate that drug concen-
trations in oral fluid may not be used to accurately estimate
drug concentrations in blood. A drug finding in oral fluid con-
firms recent drug use and may provide a semiquantitative sug-
gestion of the blood drug concentration for some drugs. For
psychiatric patients, oral fluid testing may be used as a non-in-
vasive instrument in assessing substance use. For suspected
drugged drivers, oral fluid testing may be used as initial on-site
screening before it is decided whether a blood sample should
be taken for forensic drug analysis.
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